You must be 21 years or older to access this website. All products are for research use only.
Are you 21 years of age or older?
By entering, you confirm that you are at least 21 years old and agree to our terms of service.
GLP-3 RT · Published March 8, 2026 · Updated May 18, 2026 · 8 min read
GLP-3 RT is a triple incretin receptor agonist studied in metabolic and endocrine research, engaging GLP-1, GIP, and glucagon receptors simultaneously. Studies examine peptide structure, receptor signaling, and laboratory applications across rodent metabolic disease models with multi-pathway biomarker endpoints. For research use only, not for human consumption.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
Products sold by Midwest Peptide are intended for laboratory and research use only. Not for human consumption. These products are not drugs, supplements, or intended to diagnose, treat, cure, or prevent any disease.
Retatrutide (GLP-3 RT) is a synthetic triple agonist targeting GLP-1, GIP, and glucagon receptors. It is studied in preclinical research for energy expenditure, body composition, hepatic lipid handling, and integrated metabolic endpoints.
Retatrutide's triple receptor pharmacology engages three integrated metabolic axes (incretin signaling, hepatic glucose, energy expenditure) in a single molecule, supporting integrated research questions that previously required combining multiple agents.
Endpoints include insulin and glucagon dynamics, IGF-1 axis effects, thyroid hormone profiles, leptin and adiponectin, and integrated assessment of the gut-brain-liver-adipose tissue endocrine network in rodent obesity models.
No. Retatrutide (GLP-3 RT) is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.
Key terms used in this article.
Continue exploring research insights and updates.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
The GLP-3 R peptide represents a significant advancement in scientific research focused on metabolism, glucose regulation, and endocrine function. As interest in incretin based compounds continues to grow, GLP-3 R stands out for its potential to provide deeper insight into metabolic pathways and hormonal signaling mechanisms. This compound is strictly intended for laboratory research use only.
GLP-3 R is a synthetic research peptide designed to mimic properties observed in glucagon like peptides (GLPs), which play an essential role in energy balance. In laboratory settings, GLP-3 R enables researchers to examine peptide receptor interactions and the downstream effects that contribute to metabolic adaptation.
The GLP-3 R peptide operates by engaging receptors structurally similar to those influenced by native GLP molecules. In preclinical models, this interaction helps scientists better understand receptor activation and binding affinities. Its sequence design provides a stable framework for reproducible experiments, allowing consistent results across multiple studies. By observing these mechanisms, researchers can identify patterns in cell signaling that reveal how energy metabolism and hormonal control are coordinated.
In metabolic research, GLP-3 R offers a valuable opportunity to evaluate peptide activity related to nutrient absorption, insulin sensitivity, and lipid metabolism. It has become an important subject in laboratory assays investigating how energy utilization is influenced by peptide signaling. All work with this compound should remain within the context of controlled, preclinical research.
The endocrine system governs functions from energy storage to hormonal feedback control. GLP-3 R provides a model tool for analyzing these mechanisms in vitro. Researchers can identify regulatory sequences involved in hormone release and map out signaling cascades. This may help reveal how peptide interactions contribute to communication between organs like the pancreas, liver, and gut.
GLP-3 R must be handled according to proper laboratory safety protocols. This includes storage in temperature controlled environments and restricted access to qualified personnel. Following these standards ensures the integrity of the research while maintaining compliance with regulatory guidelines.
GLP-3 RT is the research designation most commonly used by laboratory suppliers for the triple-agonist peptide retatrutide (LY3437943), an investigational analog engineered by Eli Lilly that simultaneously activates the GLP-1, GIP, and glucagon receptors. The molecule is a 39-amino-acid acylated peptide with a fatty-acid linker that extends plasma half-life into the once-weekly range, similar in design philosophy to semaglutide but with a glucagon-receptor pharmacophore deliberately retained. Where GLP-1 receptor engagement drives glucose-dependent insulin secretion and central satiety, and GIP engagement augments insulin output and modulates adipocyte lipid handling, glucagon-receptor signaling adds a thermogenic and hepatic-lipolysis component absent from single- and dual-agonist comparators. That third axis is the pharmacological reason researchers use retatrutide as a probe for energy-expenditure changes that cannot be explained by appetite suppression alone.
The published phase-2 obesity trial in the New England Journal of Medicine (NEJMoa2301972) reported up to 24.2 percent placebo-subtracted weight reduction at 48 weeks at the 12 mg dose, with a dose-response curve that was still ascending at the highest arm. The companion phase-2 study in type 2 diabetes, published in The Lancet (cagrilintide co-administration with semaglutide as a related comparator) and in subsequent retatrutide-specific Lancet papers, documented HbA1c reductions of comparable magnitude to tirzepatide alongside larger weight reductions. For preclinical investigators, these clinical anchors define the in vivo translational benchmarks that secondary-pharmacology screens should aim to reproduce in rodent models of diet-induced obesity, leptin-deficient ob/ob mice, and ZDF rats.
Mechanistic studies on retatrutide rely on receptor-specific cAMP accumulation assays in HEK293 or CHO cells stably expressing human GLP-1R, GIPR, or GCGR. Published EC50 values place the molecule in the low picomolar range at all three receptors, with a slight bias toward GIPR over GLP-1R and a deliberately weaker but still functional glucagon-receptor potency relative to native glucagon. The bias is what gives retatrutide its weight-loss-skewed phenotype while maintaining the hepatic lipolysis and energy-expenditure signature attributed to glucagon receptor engagement. Investigators replicating these assays should run a parallel tirzepatide arm as a dual-agonist reference and a semaglutide arm as a pure GLP-1R reference; the three-way comparison resolves which downstream readouts (cAMP, beta-arrestin recruitment, ERK1/2 phosphorylation) are driven by which receptor in a given cell line.
Reconstitution follows the standard lyophilized-peptide playbook. A 10 mg vial dissolved in 2 mL of bacteriostatic water gives a 5 mg/mL stock. The peptide is stable for 14 to 21 days at 4 C in low-binding polypropylene tubes; freeze-thaw cycles beyond two are not recommended because of the acyl-linker hydrolysis risk. For in vivo rodent work, weekly subcutaneous dosing in the 0.1 to 1.0 mg/kg range brackets the human-equivalent doses used in NEJM and Lancet trial reports. Body composition by EchoMRI, food intake by automated cage metrology, and indirect calorimetry are the minimum endpoint set that captures both the satiety and energy-expenditure arms of the triple-agonist phenotype.
The mechanistic question that animates most active retatrutide research is whether the glucagon-receptor contribution translates into a measurable energy-expenditure increase or whether the entire weight-loss advantage over tirzepatide can be explained by amplified satiety. Published rodent indirect-calorimetry data tilt toward a real thermogenic component: oxygen-consumption rates rise modestly at matched food-intake conditions, and brown-adipose UCP1 mRNA is up-regulated in chronic dosing arms. Hepatic effects are more pronounced. Glucagon-receptor engagement suppresses de novo lipogenesis and accelerates hepatic fatty-acid oxidation, which together explain the larger triglyceride and liver-fat reductions seen in retatrutide arms versus semaglutide or tirzepatide arms in head-to-head animal studies.
For investigators building a retatrutide assay around lipid handling rather than glucose handling, useful endpoints include hepatic triglyceride by Folch extraction, plasma ketones as a marker of mitochondrial beta-oxidation flux, and adipose-tissue gene expression panels covering UCP1, PGC-1 alpha, CIDEA, and ELOVL3. Pair these with the standard glucose-tolerance and insulin-sensitivity readouts and the resulting data set captures the full pharmacology of the molecule rather than a single-receptor slice. Cross-referenced literature on glucagon-receptor pharmacology is aggregated at the ScienceDirect glucagon-like peptide topic page and on the Cell Metabolism homepage.
Researchers selecting between semaglutide, tirzepatide, and retatrutide for a given study should anchor the choice in the mechanism of interest. Semaglutide isolates the GLP-1R contribution and is the cleanest probe for incretin-driven satiety and beta-cell signaling. Tirzepatide adds GIP engagement and is the appropriate tool for adipose-handling and lipid-storage questions. Retatrutide adds glucagon and is the tool of choice for energy-expenditure, hepatic-lipid, and combined-mechanism studies. Each peptide has its own pharmacokinetic profile and dosing cadence, and the three together form a useful titration series for dissecting which receptor contributes which fraction of a composite endpoint.
For deeper reading on related research programs, our internal guides on the GLP-3 RT cardiovascular research summary, lean-mass and muscle-sparing studies, and the triple-agonist mechanism overview collect the literature in one place. Sourcing notes are summarized in the retatrutide sourcing guide. The Frontiers in Endocrinology journal index and the Nature diabetes subject hub are useful adjacent reading for investigators building broader incretin-pharmacology reviews.
Primary literature and topic hubs from peer-reviewed publishers covering this area of research:
Explore more peer-reviewed research and laboratory guides from our science team:
All products are third-party tested with a Certificate of Analysis (COA) included. For research use only.
Browse our full catalog of research-grade peptides. Every product is third-party tested with a COA included.
Browse ProductsMidwest Peptide supplies research-grade Retatrutide (GLP-3 RT) with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.
The cheapest tirzepatide (GLP-2 TZ) for research is rarely the best value. Here is how to balance price against the analytical specifications that determine research utility.
May 5, 2026
